Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Advanced heart failure cardiology

Building Your Care Team and Preparing for Your Visit

At a Glance

Because TGCV is very rare, patients may benefit from a coordinated team that includes heart specialists, imaging experts, genetic counselors, and other clinicians. Bringing original scan files, genetic reports, biopsy records, and a symptom timeline can make specialist consultations more useful.

Because Triglyceride Deposit Cardiomyovasculopathy (TGCV) is an ultra-rare condition, your local cardiology team may not have encountered it before. Building a specialized “care team” is not just about finding more doctors; it is about finding a group of experts who can communicate with each other to manage your specific symptoms safely [1].

Your Multidisciplinary Care Team

Managing TGCV often requires several different medical specialties working together. Not every patient will need every specialist, but your core team may include:

  • Advanced Heart Failure Cardiologist: This is the “captain” of your team. They manage your complex medications, monitor your heart’s pumping strength, and evaluate you for advanced therapies if needed [1][2].
  • Interventional Cardiologist: If you have severe chest pain or blockages, you need an expert familiar with the unique “diffuse” coronary disease of TGCV and the associated restenosis risks [3][4].
  • Nuclear Medicine Specialist: This doctor is essential for interpreting your BMIPP scans. They must distinguish between a true TGCV “washout” pattern and mimicking conditions like old heart attacks [5][6].
  • Medical Geneticist or Genetic Counselor: A crucial part of the team, especially if you have or suspect Primary TGCV (P-TGCV). They help explain your PNPLA2 test results, discuss inheritance patterns (autosomal recessive), and counsel family members before any cascade testing is ordered [1][7].
  • Neurologist: If you have P-TGCV and experience signs of muscle weakness or “myopathy,” a neurologist evaluation is important [2][8].
  • Nephrologist: Kidney health is closely linked to outcomes in TGCV. If you develop chronic kidney disease, proteinuria, or have difficult fluid management issues, a kidney specialist should be involved [9][10].

Vetting Your Medical Team

When you meet a new specialist, it is helpful to ask specific questions to gauge their comfort level with this rare disease. You might ask:

  • “How many patients with TGCV or similar metabolic cardiomyopathies have you treated?”
  • “Are you familiar with the diagnostic criteria involving BMIPP washout rates?” [1]
  • “Are you open to consulting with specialized centers that focus on TGCV?”

Gathering Your Records

Because you may need second opinions from specialists in other cities, keeping a complete “medical portfolio” is essential. Your portfolio should include:

  1. BMIPP Scan Data: Not just the written report, but the actual digital images (on a CD or USB) of the “early” and “delayed” scans [5].
  2. Coronary Imaging: CDs of your angiograms or CT scans showing the pattern of your arteries [4].
  3. Genetic Reports: The full technical report for your PNPLA2 gene testing [1].
  4. Pathology/Biopsy Results: If you had a heart biopsy, ask for the pathology report and any electron microscopy images [11].
  5. A Symptom Timeline: A dated list of when your symptoms started, any hospitalizations, and a family history of heart or muscle disease.

The Role of Registries

Because TGCV is so rare, your doctor may ask you if you wish to join an observational registry [12].

  • What it is: Registries gather long-term data from many patients to help researchers understand the “natural history” of the disease—how it progresses over time [1].
  • Important Context: Participation is entirely voluntary and requires your informed consent regarding data privacy. Joining a registry does not replace your clinical care and does not guarantee access to investigational clinical trials (like those for tricaprin/CNT-01) [13][14]. However, it ensures your anonymized experience contributes to the global understanding of the condition.

Common questions in this guide

What kind of specialists may be part of a TGCV care team?
A team may include an advanced heart failure cardiologist and an interventional cardiologist, with a nuclear medicine specialist to interpret BMIPP scans. Depending on your symptoms and test results, medical genetics or genetic counseling, neurology, and nephrology may also be involved.
What should I bring to an appointment for TGCV?
Bring the original digital files for early and delayed BMIPP scans, coronary angiograms or CT images, and the complete PNPLA2 genetic report. If you had a biopsy, include the pathology report and any electron microscopy images, along with a dated symptom and family-history timeline.
How can I assess whether a doctor knows how to manage TGCV?
Ask how many patients with TGCV or similar metabolic heart diseases they have treated and whether they understand BMIPP washout patterns. It is also reasonable to ask whether they will consult a specialized TGCV center and coordinate with your local team.
Why are the actual BMIPP scan images important?
A nuclear medicine specialist may need to compare the early and delayed BMIPP images and assess the washout pattern alongside your symptoms. This helps distinguish a TGCV pattern from changes that may follow an old heart attack.
When should someone with primary TGCV see a genetic counselor?
Genetic counseling can help explain PNPLA2 test results and the autosomal recessive inheritance pattern associated with primary TGCV. A counselor can also discuss what the results may mean for relatives before family testing is considered.
What should I know before joining a TGCV registry?
An observational registry is voluntary and requires informed consent about data privacy and how information will be used. Participation can help researchers understand how TGCV changes over time, but it does not replace medical care or guarantee access to investigational trials such as tricaprin/CNT-01.

Get notified when new evidence is published on Triglyceride deposit cardiomyovasculopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (14)
  1. 1

    Triglyceride deposit cardiomyovasculopathy: A new class of cardiovascular disease.

    Mori T, Hirano KI, Miyauchi H, et al.

    Journal of cardiology 2026; (88(4)):255-267 doi:10.1016/j.jjcc.2026.04.003.

    PMID: 41980667
  2. 2

    ATGL Deficiency-Induced Triglyceride Deposit Cardiomyovasculopathy Requiring Heart Transplant: A 5-Year Follow-Up.

    Rajani P, Robertus JL, Wong J, et al.

    JACC. Case reports 2020; (2(5)):760-763 doi:10.1016/j.jaccas.2020.03.021.

    PMID: 34317343
  3. 3

    Triglyceride deposit cardiomyovasculopathy as a predictor of vascular failure after coronary intervention in patients with hemodialysis: a preliminary analysis.

    Fujimoto M, Nakano Y, Hirano KI, et al.

    Renal failure 2026; (48(1)):2650580 doi:10.1080/0886022X.2026.2650580.

    PMID: 42015807
  4. 4

    Durable Vessel Patency Achieved by Drug-Coated Balloon-Only Percutaneous Coronary Intervention in Triglyceride Deposit Cardiomyovasculopathy.

    Uchiumi K, Nakano Y, Katsuki S, et al.

    JACC. Case reports 2026; 110636 doi:10.1016/j.jaccas.2026.110636.

    PMID: 42853169
  5. 5

    Practice recommendation for measuring washout rates in 123I-BMIPP fatty acid images.

    Nakajima K, Miyauchi H, Hirano KI, et al.

    Annals of nuclear medicine 2024; (38(1)):1-8 doi:10.1007/s12149-023-01863-8.

    PMID: 37691078
  6. 6

    Visual Differentiation Between Triglyceride Deposit Cardiomyovasculopathy and Old Myocardial Infarction Using Count-Washout Rate Polar Map in Iodine-123-β-Methyl-p-Iodophenyl-Pentadecanoic Acid Scintigraphy.

    Ono R, Hoshi K, Miyauchi H, Kobayashi Y

    Annals of nuclear cardiology 2025; (11(1)):20-25 doi:10.17996/anc.24-00012.

    PMID: 41368555
  7. 7

    A novel homozygous missense mutation in PNPLA2 in a patient manifesting primary triglyceride deposit cardiomyovasculopathy.

    Hara Y, Ikeda Y, Kimura H, et al.

    Molecular genetics and metabolism reports 2023; (34()):100960 doi:10.1016/j.ymgmr.2023.100960.

    PMID: 36846631
  8. 8

    Neutral Lipid Storage Disease Associated with the PNPLA2 Gene: Case Report and Literature Review.

    Samukawa M, Nakamura N, Hirano M, et al.

    European neurology 2020; (83(3)):317-322 doi:10.1159/000508346.

    PMID: 32564019
  9. 9

    Chronic kidney disease is a major risk factor for mortality in triglyceride deposit cardiomyovasculopathy patients.

    Nagasawa Y, Okamura S, Nishimura Y, et al.

    Clinical and experimental nephrology 2025; (29(6)):866-871 doi:10.1007/s10157-024-02618-z.

    PMID: 39809936
  10. 10

    Prevalence and clinical outcomes of triglyceride deposit cardiomyovasculopathy among haemodialysis patients.

    Onishi T, Nakano Y, Hirano KI, et al.

    Heart (British Cardiac Society) 2021; (107(2)):127-134 doi:10.1136/heartjnl-2020-317672.

    PMID: 32998957
  11. 11

    Additional diagnostic value of electron microscopic examination in endomyocardial biopsy in patients with suspected non-ischemic cardiomyopathy.

    Yamamoto M, Sato K, Murakoshi N, et al.

    Journal of cardiology 2023; (81(2)):236-243 doi:10.1016/j.jjcc.2022.09.012.

    PMID: 36182004
  12. 12

    Triglyceride deposit cardiomyovasculopathy: a rare cardiovascular disorder.

    Li M, Hirano KI, Ikeda Y, et al.

    Orphanet journal of rare diseases 2019; (14(1)):134 doi:10.1186/s13023-019-1087-4.

    PMID: 31186072
  13. 13

    123I-BMIPP Scintigraphy Shows That CNT-01 (Tricaprin) Improves Myocardial Lipolysis in Patients with Idiopathic Triglyceride Deposit Cardiomyovasculopathy: First Randomized Controlled, Exploratory Trial for TGCV.

    Miyauchi H, Hirano KI, Nakano Y, et al.

    Annals of nuclear cardiology 2022; (8(1)):67-75 doi:10.17996/anc.22-00167.

    PMID: 36540180
  14. 14

    Long-term survival and durable recovery of heart failure in patients with triglyceride deposit cardiomyovasculopathy treated with tricaprin.

    Hirano KI, Okamura S, Sugimura K, et al.

    Nature cardiovascular research 2025; (4(3)):266-274 doi:10.1038/s44161-025-00611-7.

    PMID: 39948308

This page is for informational purposes only and does not constitute medical advice. Your cardiologist and specialized TGCV care team should interpret your scans, genetic results, and treatment options.